Introduction {#Sec1}
============

Cancer is an essential public health problem and a major cause of death worldwide. In 2019, Approximately 1,762,450 cancer cases will be diagnosed and 606,880 cancer patients will die in America as estimated by the American Cancer Society^[@CR1]^. Although great advances in diagnoses and treatments have improved survival, the prognosis of patients with advanced cancers remains poor^[@CR2]^. The exploration of novel therapeutic targets and prognostic biomarkers is a top priority. LncRNAs, comprising more than 200 nucleotides, are engaged in many biological processes, such as cell proliferation, differentiation, the DNA damage response and chromosomal imprinting^[@CR3],[@CR4]^. A large number of studies have suggested that lncRNAs are tightly linked with oncogenicity and cancer progression^[@CR5]--[@CR7]^.

An antisense RNA to the TP73 gene (TP73-AS1), also named *KIAA0495*/PDAM, is located in the 1p36 chromosome region that is frequently deleted in tumors and comprises tumor suppressor genes^[@CR8]^. TP73-AS1 functions as a tumor suppressor by sponging miR-941 at nine high-affinity binding sites^[@CR9]^. TP73-AS1 can suppress the progression of bladder cancer by epithelial-mesenchymal transition (EMT), and low TP73-AS1 expression predicts a shorter survival of bladder cancer patients^[@CR10]^. However, TP73-AS1 also acts as a tumor promoter. For example, TP73-AS1 can promote hepatocellular carcinoma (HCC) cell proliferation via miR-200a-dependent HMGB1/RAGE regulation, and its high expression level is significantly associated with a poorer prognosis of HCC patients^[@CR11]^. Knockdown of TP73-AS1 suppresses the proliferation and invasion of osteosarcoma cells by sponging miR-142^[@CR12]^. TP73-AS1, which is upregulated in cholangiocarcinoma (CCA) tissues, predicts adverse phenotypes for CCA, and silencing TP73-AS1 attenuates CCA cell proliferation, migration and invasion^[@CR13]^.

Therefore, we performed this meta-analysis based on studies focusing on the association of TP73-AS1 with survival and clinicopathological features. We aimed to explore the potential of TP73-AS1 as a novel biomarker and therapeutic target.

Materials and methods {#Sec2}
=====================

Search strategy {#Sec3}
---------------

Two authors (Yuan Zhong and Yang Yu) independently screened PubMed, Web of Science, the Cochrane Library and Embase up to February 21,2019. The search terms were used as follows: ("TP73-AS1" OR "P73 antisense RNA 1 T" OR "antisense RNA to TP73 gene" OR "KIAA0495" OR "PDAM") AND ("cancer" OR "tumor" OR "carcinoma" OR "neoplasm").

Selection criteria {#Sec4}
------------------

Inclusion criteria were as follows: (1) TP73-AS1 expression was detected in cancer tissues; (2) Patients were divided into two groups based on TP73-AS1 expression levels; (3) The association between TP73-AS1 expression and the prognosis of patients with cancer was investigated; and (4) Sufficient data were extracted to compute the HR and 95% CI of survival or the OR and 95% CI of clinicopathological parameters. Exclusion criteria were as follows: (1) Nonhuman studies, reviews, editorials, expert opinions, letters, and case reports; (2) Studies lacking key data; and (3) Duplicate publications.

Data extraction and quality assessment {#Sec5}
--------------------------------------

Two authors extracted the following requisite data in each qualified article: first author's name, publication year, country, cancer type, sample type, sample size, detection method, cut-off value, the number of patients in the high and low TP73-AS1 expression groups, survival analysis method, the HR and 95% CI of TP73-AS1 for survival and data for age, gender, TNM stage, tumor size, lymph node metastasis, etc. If the HR was not accessible from the original text, we utilized Engauge Digitizer v.10.11 software to extract data from the Kaplan-Meier survival curve and calculated the HR with assistance from Tierney's spreadsheet^[@CR14]^. The HR with the 95% CI from multivariate analysis was preferred over that from the univariate analysis because the multivariate analysis considered the effects of other factors. Two authors independently assessed the quality of each eligible study under the guidance of the Newcastle-Ottawa Quality Assessment Scale (NOS)^[@CR15]^.

Statistical analysis {#Sec6}
--------------------

Pooled HRs with 95% CIs were calculated to investigate the value of TP73-AS1 on the survival of patients with cancer. Pooled ORs with 95% CIs were used to evaluate the association between TP73-AS1 expression and clinicopathological features. The heterogeneity of the pooled results was explored by means of the Q test and I^[@CR2]^ statistics. The fixed pooling model was selected when I^2^ \< 50% and p \> 0.10. Otherwise, the random pooling model was used. Subgroup analysis was further conducted to explore the potential sources of heterogeneity. Sensitivity analysis was performed to test whether each single study could influence the stability of the results. Egger's test was utilized to assess a publication bias. A p value less than 0.05 was considered statistically significant.

Results {#Sec7}
=======

Characteristics of the included studies {#Sec8}
---------------------------------------

A total of 19 articles were eligible for this meta-analysis according to the selection criteria^[@CR9]--[@CR13],[@CR16]--[@CR27]^. In total, 1329 patients with 13 types of cancer, including GC^[@CR9],[@CR16]--[@CR18]^, breast cancer^[@CR13],[@CR19]^, ovarian cancer^[@CR20],[@CR21]^, osteosarcoma^[@CR12],[@CR22]^, brain glioma^[@CR23]^, hepatocellular carcinoma (HCC)^[@CR11]^, cholangiocarcinoma (CCA)^[@CR13]^, colorectal cancer (CRC)^[@CR27]^, pancreatic cancer^[@CR24]^, lung adenocarcinoma (LAD)^[@CR25]^, non-small cell lung cancer (NSCLC)^[@CR19]^, bladder cancer^[@CR10]^ and clear cell renal cell carcinoma (ccRCC)^[@CR26]^, were analyzed. Twelve articles chose overall survival (OS) as the only survival outcome^[@CR9],[@CR11]--[@CR13],[@CR17]--[@CR19],[@CR21]--[@CR25]^, 2 articles used both OS and disease-free survival (DFS)^[@CR16],[@CR26]^, and one article used both OS and progression-free survival (PFS)^[@CR10]^. All studies were performed in China. TP73-AS1 expression levels were measured by quantitative real-time PCR (qRT-PCR). Patients were classified into high or low expression groups according to the cut-off value. More details are shown in Fig. [1](#Fig1){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}.Figure 1Flow diagram of this meta-analysis.Table 1Characteristics of the included studies.CancerFirst authorYearCountrySample typeSample size(n)Detection methodCut-off valuePTSurvival analysisMultivariate analysisHazard ratiosNOS scoreGCWei Zhang^[@CR9]^2018ChinaTissue76qRT-PCRNAnoOSNoK-M curve7GCYufeng Wang^[@CR16]^2018ChinaTissue64qRT-PCRNANAOS, DFSNoK-M curve6GCJianjun Peng^[@CR17]^2018ChinaTissue58qRT-PCRmeannoOSYesK-M curve6GCZhi Ding^[@CR18]^2018ChinaTissue72qRT-PCRmediannoOSnoK-M curve6Breast cancerQiongyan Zou^[@CR19]^2017ChinaTissue86qRT-PCRmedianNANANoNA8Breast cancerJia Yao^[@CR13]^2017ChinaTissue36qRT-PCR2-foldNAOSYesText7Ovarian cancerXiaoqian Wang^[@CR20]^2018ChinaTissue60qRT-PCRmedianNANANoNA8Ovarian cancerXiuyun Li^[@CR34]^2018ChinaTissue62qRT-PCRmeannoOSYesK-M curve6OsteosarcomaXi Chen^[@CR35]^2018ChinaTissue132qRT-PCRNAnoOSYesText7OsteosarcomaGuangling Yang^[@CR12]^2018ChinaTissue46qRT-PCRmeannoOSNoK-M curve8Brain gliomaRong Zhang^[@CR23]^2017ChinaTissue47qRT-PCRmedianNAOSYesText7HCCShaling Li^[@CR11]^2017ChinaTissue84qRT-PCRmedianNAOSnoK-M curve8Pancreatic cancerXianping Cui^[@CR24]^2019ChinaTissue77qRT-PCRNANAOSNoK-M curve7LADChunfeng Liu^[@CR25]^2019ChinaTissue80qRT-PCRmediannoOSYesK-M curve7NSCLCLin Zhang^[@CR19]^2018ChinaTissue45qRT-PCRmedianNAOSNoK-M curve7Bladder cancerZhiyong Tuo^[@CR10]^2018ChinaTissue128qRT-PCRmediannoOS, PFSNoK-M curve7ccRCCGuanghua Liu^[@CR26]^2018ChinaTissue40qRT-PCRmediannoOS, DFSNoK-M curve8CCAYue Yao^[@CR13]^2018ChinaTissue75qRT-PCRmeannoNANoNA8CRCZeming Jia^[@CR27]^2019ChinaTissue61qRT-PCRNAnoNANoNA7Abbreviations: GC, gastric cancer; HCC, hepatocellular carcinoma; LAD, lung adenocarcinoma; NSCLC, non-small cell lung cancer; ccRCC, clear cell renal cell carcinoma; CCA, cholangiocarcinoma; CRC, colorectal cancer; PT, preoperative treatment; NA, Not available.

Association between TP73-AS1 and survival {#Sec9}
-----------------------------------------

TP73-AS1 was relatively upregulated in most cancer tissues compared to paired normal or non-cancerous tissues except for bladder cancer specimens. As shown in Fig. [2](#Fig2){ref-type="fig"}, high TP73-AS1 expression was significantly associated with poor OS (HR = 1.962, 95% CI 1.630-2.362) with mild heterogeneity (I^2^ = 34.9%) and short DFS (HR = 2.050, 95% CI 1.293-3.249). High TP73-AS1 expression only in bladder cancer indicated long OS (HR = 0.400, 95% CI 0.180-0.880).Figure 2Forest plots for association of TP73-AS1 expression with overall survival (OS) and disease-free survival (DFS). Abbreviations: GC, gastric cancer; HCC, hepatocellular carcinoma; LAD, lung adenocarcinoma; NSCLC, non-small cell lung cancer; ccRCC, clear cell renal cell carcinoma.

Subgroup analysis of the association between TP73-AS1 and OS was performed by examining TP73-AS1 expression in cancer tissue (high or low), cancer type (digestive system or non-digestive system), analysis method (multivariate analysis or univariate analysis) and NOS score (≥7 or \<7), as shown in Table [2](#Tab2){ref-type="table"}. The result of each subgroup was not significantly changed. Subgroup analysis revealed that differential expression of TP73-AS1 in cancer tissues was the potential source of heterogeneity.Table 2Subgroup analysis of the pooled HRs for OS.Subgroup analysisNumber of studiesNumber of patientsHR (95% CI)P valueHeterogeneityI^[@CR2]^P valueOverall1510471.962 (1.630-2.362)p \<0.00134.9%0.09**Expression in cancer tissue**High149192.151 (1.777-2.603)p \<0.0010.0%0.971Low11280.400 (0.181-0.884)0.024NANACancer typeDigestive system64312.124 (1.629-2.770)p \<0.0010.0%0.671Non-digesstive system96161.837 (1.230-2.744)0.00354.6%0.024**Analysis method**Multivariate analysis64152.452 (1.816-3.310)p \<0.0010.0%0.653Univariate analysis96321.709 (1.350-2.164)p \<0.00145.8%0.064NOS score≥7117911.803 (1.449-2.244)p \<0.00139.2%0.088\<742562.437 (1.716-3.461)p \<0.0010.5%0.389

Four studies focusing on GC showed that high TP73-AS1 expression markedly predicted poor OS (HR = 2.101, 95% CI 1.516-2.911). Two studies on osteosarcoma demonstrated that high TP73-AS1 expression was significantly correlated with short OS (HR = 1.920, 95% CI 1.253-2.942). More details are provided in Fig. [3](#Fig3){ref-type="fig"}.Figure 3Forest plots for association of TP73-AS1 expression with overall survival (OS) in gastric cancer (GC) and osteosarcoma.

Association between TP73-AS1 and clinicopathological features {#Sec10}
-------------------------------------------------------------

The results demonstrated that high TP73-AS1 expression was not significantly associated with the age or gender of cancer patients (age: OR = 1.082, 95% CI 0.817-1.433; gender: OR = 1.034, 95% CI 0.772-1.385). As shown in Fig. [4](#Fig4){ref-type="fig"}, high TP73-AS1 expression was significantly related to large tumor size (OR = 2.759, 95% CI 1.759-4.330), advanced histological grade (OR = 2.394, 95% CI 1.231-4.656), lymph node metastasis (OR = 2.687, 95% CI 1.211-5.962), distant metastasis (OR = 4.145, 95% CI 2.252-7.629) and advanced TNM stage (OR = 2.633, 95% CI 1.507-4.601).Figure 4Forest plots for association of TP73-AS1 expression with clinicopathological features: (**A**) Tumor size; (**B**) Histological grade; (**C**) Distant metastasis; (**D**) Lymph node metastasis; (**E**) TNM stage.

In Fig. [5](#Fig5){ref-type="fig"}, studies on GC showed that high TP73-AS1 expression was significantly associated with lymph node metastasis (OR = 3.792, 95% CI 1.793-8.018) and large tumor size (OR = 2.137, 95% CI 1.087-4.203) in GC patients. Two articles on breast cancer demonstrated that high TP73-AS1 expression was significantly linked with large tumor size (OR = 4.201, 95% CI 1.961-8.999), advanced TNM stage (OR = 5.764, 95% CI 2.637-12.598) and the absence of lymph node metastasis (OR = 0.234, 95% CI 0.057-0.966) but not with ER status (OR = 1.220, 95% CI 0.596-2.497) or PR status (OR = 1.700, 95% CI 0.828-3.491). Two studies on osteosarcoma supported that high TP73-AS1 expression was notably associated with advanced clinical stage (OR = 3.184, 95% CI 1.732-5.854) and distant metastasis (OR = 4.730, 95% CI 2.225-10.053) but not with tumor site (OR = 0.650, 95% CI 0.309-1.366). Two studies concerning ovarian cancer revealed an association of TP73-AS1 with lymph node metastasis (OR = 6.616, 95% CI 3.241-13.504) and histological grade (OR = 2.129, 95% CI 1.046-4.336). Moreover, two articles showed a significant association of TP73-AS1 with lymph node metastasis (OR = 8.139, 95% CI 1.990-33.282) and advanced FIGO stage (OR = 9.514, 95% CI 2.542-35.604) but not with histological grade (OR = 2.333, 95% CI 0.251-21.682).Figure 5Forest plots for association of TP73-AS1 expression with clinicopathological features in 3 cancers: (**A**) Gastric cancer; (**B**) Osteosarcoma; (**C**) Ovarian cancer.

Publication bias and sensitivity analysis {#Sec11}
-----------------------------------------

Egger's test was conducted to explore a possible publication bias. As shown in Fig. [6](#Fig6){ref-type="fig"}, the symmetrical Egger's plot of all eligible studies for OS showed no significant publication bias(p = 0.633).Figure 6Egger's test for publication bias of results of overall survival (OS).

Sensitivity analysis was performed to estimate the stability of the original OS results. The robustness of the meta-analysis conclusions was confirmed because the results were not altered significantly when any study was eliminated (Fig. [7](#Fig7){ref-type="fig"}).Figure 7Sensitivity analysis for studies about OS by omitting each study sequentially.

Discussion {#Sec12}
==========

A large number of articles have identified that lncRNAs such as lncRNA PVT1, lncRNA HULC, and lncRNA CRNDE are closely related to the initiation and progression of various cancers and could serve as prognostic biomarkers^[@CR28]--[@CR30]^. TP73-AS1 was initially described in a study on oligodendroglial tumors, which revealed that TP73-AS1 was downregulated in tumor samples mainly via epigenetic modifications and chromosome 1p loss, and the knockdown of TP73-AS1 induced cisplatin resistance in glioma cells^[@CR31]^. High TP73-AS1 expression was associated with larger tumor size, advanced WHO stage and a shorter OS in glioma patients^[@CR23]^. Tuo et al. reported that low TP73-AS1 expression predicted unfavorable survival and diminished bladder cancer cell proliferation, migration and invasion but facilitated apoptosis^[@CR10]^. In contrast, TP73-AS1 promoted oesophageal cancer cell proliferation and inhibited apoptosis^[@CR32]^. Knockdown of TP73-AS1 inhibited the vasculogenic mimicry formation of triple-negative breast cancer cells by targeting the miR-490-3p/TWIST1 axis^[@CR33]^. Liu et al. revealed that TP73-AS1, upregulated ccRCC tissues, predicted the prognosis of ccRCC patients and promoted ccRCC cell proliferation and invasion but inhibited apoptosis^[@CR26]^. These discrepancies show the different roles of TP73-AS1 in multiple cancers.

In this meta-analysis, nineteen eligible studies with 1329 cancer patients were included. Pooled results indicated that TP73-AS1 overexpression was significantly associated with poor OS and DFS. The association of TP73-AS1 with OS was robust in either gastric cancer or osteosarcoma. Subgroup analysis of OS indicated no significant change in any subgroup. Furthermore, high TP73-AS1 expression was markedly related to larger tumor size, lymph node metastasis, distant metastasis, advanced TNM stage and histological grade but not with age or gender.

Furthermore, we payed attention to potential targets and pathways of TP73-AS1 in the included cancers (Table [3](#Tab3){ref-type="table"}). TP73-AS1 functioned as an oncogenic lncRNA in most cancers except bladder cancer and CRC. In this meta-analysis, high TP73-AS1 expression was associated with long OS only in bladder cancer. Tuo et al. found that in bladder cancer overexpression of TP73-AS1 could inhibit cell growth, arrest cell cycle, reduce cell migration and invasion, promote cell apoptosis, and diminish EMT by inhibiting the expression of vimentin, snail, MMP-2, and MMP-9 and upregulating the expression of E-cadherin^[@CR10]^. On the contrary, TP73-AS1 could promote tumor progression through regulating HMGB1/RAGE pathway in GC, brain glioma and HCC. TP73-AS1 could target miR-142 both in osteosarcoma and brain glioma. In addition, TP73-AS1 was linked to chemoresistance in both GC and glioblastoma. TP73-AS1 might not only act as a biomarker of chemosensitivity, but also as a novel therapeutic target.Table 3Summary of potential targets and pathways of TP73-AS1.Cancer typeExpressionPotential targetPathwayReferencesGCUpregulatedNACell proliferation, apoptosis, invasion and metastatic properties; tumorigenesis; cisplatin resistance; Bcl-2/caspase-3 pathway; EMT; WNT/β-catenin signaling pathway; HMGB1/RAGE signaling pathway; miR-194-5p/SDAD1 axis^[@CR9],[@CR16]--[@CR18]^Breast cancerUpregulatedmiR-200a; miR-490-3pCell invasion, migration and vasculogenic mimicry; TFAM; TP73-AS1/miR-200a/ZEB1 regulating loop; miR-490-3p/TWIST1 axis^[@CR13],[@CR19],[@CR33]^Ovarian cancerUpregulatedp21; EZH2Cell proliferation, apoptosis, invasion and migration; tumor growth; MMP2 and MMP9^[@CR20],[@CR21],[@CR36]^OsteosarcomaUpregulatedmiR-142Cell proliferation, migration and invasion; tumor growth; TP73-AS1/miR-142/Rac1 signaling pathway^[@CR12],[@CR22]^Brain gliomaUpregulatedmiR-142; miR-124Cell proliferation and invasion; temozolomide resistance; HMGB1/RAGE pathway; ALDH1A1; TP73-AS1/miR-124/iASPP axis^[@CR23],[@CR37],[@CR38]^HCCUpregulatedmiR-200aCell proliferation; HMGB1/RAGE pathway and NF-кB expression^[@CR11]^Pancreatic cancerUpregulatedmiR-141Cell migration, invasion and metastasis; BDH2^[@CR24]^LADUpregulatedNACell proliferation, apoptosis, migration and invasion; tumor growth and metastasis; PI3K/AKT pathway^[@CR25]^NSCLCUpregulatedmiR-449aCell growth and cycle progression; TP73-AS1/miR-449a/EZH2 axis^[@CR19]^Bladder cancerDownregulatedNACell proliferation, apoptosis, migration and invasion; EMT^[@CR10]^ccRCCUpregulatedKISS1Cell proliferation, invasion and apoptosis; PI3K/Akt/mTOR pathway^[@CR26]^CCAUpregulatedNACell proliferation, apoptosis and metastatic properties; tumor growth^[@CR13]^CRCDownregulatedmiR-103; miR-194Cell proliferation, apoptosis migration and invasion; tumor growth; TP73-AS1/miR-103 axis; PTEN; TP73-AS1/miR-194/TGFα axis^[@CR27],[@CR39]^

The limitations of this meta-analysis deserve to be mentioned. First, each study was conducted in China, which means that the results need to be verified by studies from other countries. Second, most studies had a small sample size (n \< 100), which might result in inflated estimates of effect size. Third, the cut-off values were not available in 5 studies. Finally, we calculated the HRs from Kaplan-Meier curves in 12 studies, which may have affected the accuracy of the results.

Conclusion {#Sec13}
==========

High TP73-AS1 expression in multiple cancers predicted poor OS, poor DFS, larger tumor size, lymph node metastasis, distant metastasis, advanced TNM stage and histological grade. TP73-AS1 might be a novel prognostic biomarker and therapeutic target for cancers. More high-quality studies with a large sample size and a standardized methodologic design are required to further certify the prognostic value of TP73-AS1 in cancers.
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